Fox Run Management, L.L.C. Editas Medicine, Inc. Transaction History

Fox Run Management, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	BUY	$12.16 - $19.42 $171,687 - $274,190	14,119 New	14,119 $173,000
Q4 2021 Feb 09, 2022	SELL	$26.55 - $40.57 $279,677 - $427,364	-10,534 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $413,670 - $768,349	10,534 New	10,534 $433,000
Q1 2021 May 17, 2021	SELL	$39.71 - $90.58 $117,859 - $268,841	-2,968 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$27.07 - $84.35 $80,343 - $250,350	2,968 New	2,968 $208,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.